Drug Trial Radar · NCT05668988
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
324
Actual
Start
Dec 13, 2022
Primary completion
Jan 16, 2026
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Dec 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).
Conditions
- Non-small Cell Lung Cancer
Interventions
sunvozertinibDrug
orally, 300 mg, once daily until a treatment discontinuation criterion is met.
Pemetrexed+carboplatinDrug
Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) per RECIST 1.1Time frame: Up to approximately 34 months after the first participant is randomized
Locations
154 sites in 15 countries. Site status is shown where the registry gives one.
OPN Healthcare, Inc.
Glendale, California
Kaiser Permanente Medical Center
Vallejo, California
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
D&H Cancer Research Center LLC
Margate, Florida
BRCR Medical Center Inc.
Plantation, Florida
NYU Langone Health
New York, New York
NYU Laura & Issac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Columbia University Medical Center
New York, New York
Gabrail Cancer Center Research
Canton, Ohio
OSU Brain & Spine Hospital
Columbus, Ohio
Providence Portland Institute Franz
Portland, Oregon
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
The University of Texas MD Anderson cancer center
Houston, Texas
exas Oncology--McAllen
Weslaco, Texas
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Centro Medico Austral
Buenos Aires, Argentina
Consultorios Medicos Dr. Doreski - Fundacion Respirar
Buenos Aires, Argentina
Fundacion Cenit Para El Estudio De Neurociencias
Buenos Aires, Argentina
Instituto Argentino de Diagnositco y Tratamiento S.A
Buenos Aires, Argentina
Fundación Estudios Clínicos
Rosario, Argentina
Fundación Ars Médica
San Salvador, Argentina
Concord Repatriation General Hospital
Concord, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Prince of Wales Hospital
Randwick, Australia
Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria
Uniklinikum Salzburg Universitatsklinik fur Innere Medizin Ⅲ
Salzburg, Austria
Universitair Ziekenhuis Antwerpen
Edegem, Antwerp, Belgium
UZ Gent
Ghent, Flanders, Belgium
Grand Hopital de Charleroi
Charleroi, Hainaut, Belgium
Fundacao PIO XII - Hospital do Cancer de Barretos
Barretos, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Brazil
Liga Norte Riograndense Contra o Câncer
Natal, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Uniao Brasileira de Educacao e Assistencia - Hospital São Lucas da PUCRS
Porto Alegre, Brazil
Instituto D'Or de Pesquisa e Ensino
Recife, Brazil
Instituto D'Or de Pesquisa e Ensino
Rio de Janeiro, Brazil
Instituto de Educacao, Pesquisa d Gestao em Saude
Rio de Janeiro, Brazil
Instituto Nacional de Cancer - INCA
Rio de Janeiro, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, Brazil
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.